News

Under the agreement, Adamis Pharma and Beximco Pharma plan to introduce four generic respiratory drug formulations in the US market over the next three years. The two companies

Cyclophosphamide is the active drug used in Revimmune therapy, Accentia‘s proprietary system-of-care being developed for the treatment of a broad range of autoimmune diseases. The agreement also grants

The article, published in International Journal of Pharmaceutics, entitled, ‘Enhanced in vitro Transbuccal Drug Delivery of Ondansetron HCl,’ highlights NexACT enhancers’ ability to significantly improve permeation of ondansetron,

The DESSOLVE I study is a prospective, open-label, non-randomized, single-arm study that is expected to enroll 30 patients at five clinical sites in Belgium, Australia and New Zealand.

GSK said that successful implementation of the Patent Box will secure new investment in the manufacture of the company’s next generation high-technology respiratory inhalation device for asthma and

Following this purchase, GSK will own 15,151,499 shares of Theravance common stock and Class A common stock, which represent approximately 19% of the total outstanding capital stock of

China Pediatric Pharma claims that a significant portion of the increase in sales is derived from an increase in sales for the ‘Cooer’ Series by $2.6m or 80%

Immunovaccine claims that its DepoVax platform is a lipid depot-based vaccine delivery and enhancement technology. Immunovaccine is currently testing the safety and tolerability of DepoVax in a Phase

Eisai said that SEP-190 is a non-benzodiazepine type GABAA agonist (non-benzodiazepine sedative hypnotic) that is effective in treating transient and chronic insomnia and that can be used over